Daily News Podcast

Brain damage, slight benefit seen in epinephrine cardiac arrest


 

Epinephrine provided a slight 30-day survival benefit, but those patients experienced more severe brain damage. Also today, nerve growth factor inhibitor shows phase-3 efficacy in osteoarthritis, National Academies issues a 5-step plan to address infections linked to opioid use disorder, and there may be beneficial class effects of SGLT2 inhibitors, including dapagliflozin. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Solriamfetol could improve sleep measures
MDedge Hematology and Oncology
Sjögren’s syndrome recommendations are close
MDedge Hematology and Oncology
Judge Brett Kavanaugh and the ACA
MDedge Hematology and Oncology
New guidelines could mean millions more with hypertension
MDedge Hematology and Oncology
AHRQ National Guideline Clearinghouse shutting down
MDedge Hematology and Oncology
Less documentation highlights new Medicare fee proposal
MDedge Hematology and Oncology
Too many antibiotics prescribed in urgent care
MDedge Hematology and Oncology
Managing HIV with diabetes
MDedge Hematology and Oncology
Telemedicine payment expansion?
MDedge Hematology and Oncology
Bundle pay plan didn’t save money
MDedge Hematology and Oncology